PMID- 34484124
OWN - NLM
STAT- MEDLINE
DCOM- 20220211
LR  - 20221207
IS  - 1664-2392 (Print)
IS  - 1664-2392 (Electronic)
IS  - 1664-2392 (Linking)
VI  - 12
DP  - 2021
TI  - Switching From Daily DPP-4 Inhibitor to Once-Weekly GLP-1 Receptor Activator 
      Dulaglutide Significantly Ameliorates Glycemic Control in Subjects With Poorly 
      Controlled Type 2 Diabetes Mellitus: A Retrospective Observational Study.
PG  - 714447
LID - 10.3389/fendo.2021.714447 [doi]
LID - 714447
AB  - AIM: At present, daily DPP-4 inhibitors are quite frequently prescribed in 
      subjects with type 2 diabetes mellitus (T2DM). Recently, it has been drawing much 
      attention that once-weekly incretin-based injection dulaglutide was developed. In 
      this study, we aimed to examine the possible effects of once-weekly GLP-1 
      receptor activator (GLP-1RA) dulaglutide on glycemic control as well as various 
      metabolic parameters. METHODS: We made a direct comparison between the effect of 
      daily DPP-4 inhibitor and once-weekly dulaglutide on glycemic control in "study 1 
      (pre-post comparison)" and set the control group using the propensity score 
      matching method in "study 2". RESULTS: In study 1, switching from daily DPP-4 
      inhibitor to dulaglutide significantly ameliorated glycemic control in subjects 
      with T2DM. Such effects were more obvious in poorly controlled subjects. After 
      1:1 propensity score matching, the switching group improved glycemic control 
      compared with the non-switching group in study 2. CONCLUSION: We should bear in 
      mind that switching from daily DPP-4 inhibitor to once-weekly GLP-1RA dulaglutide 
      exerts more favorable effects on glycemic control regardless of age, body weight, 
      and duration of diabetes in subjects with T2DM, especially when we fail to obtain 
      good glycemic control with daily DPP-4 inhibitor.
CI  - Copyright (c) 2021 Sanada, Kimura, Shimoda, Tomita, Fushimi, Kinoshita, Obata, 
      Okauchi, Hirukawa, Kohara, Tatsumi, Nakanishi, Mune, Kaku and Kaneto.
FAU - Sanada, Junpei
AU  - Sanada J
AD  - Department of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, 
      Kurashiki, Japan.
FAU - Kimura, Tomohiko
AU  - Kimura T
AD  - Department of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, 
      Kurashiki, Japan.
FAU - Shimoda, Masashi
AU  - Shimoda M
AD  - Department of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, 
      Kurashiki, Japan.
FAU - Tomita, Akiko
AU  - Tomita A
AD  - Department of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, 
      Kurashiki, Japan.
FAU - Fushimi, Yoshiro
AU  - Fushimi Y
AD  - Department of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, 
      Kurashiki, Japan.
FAU - Kinoshita, Tomoe
AU  - Kinoshita T
AD  - Department of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, 
      Kurashiki, Japan.
FAU - Obata, Atsushi
AU  - Obata A
AD  - Department of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, 
      Kurashiki, Japan.
FAU - Okauchi, Seizo
AU  - Okauchi S
AD  - Department of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, 
      Kurashiki, Japan.
FAU - Hirukawa, Hidenori
AU  - Hirukawa H
AD  - Department of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, 
      Kurashiki, Japan.
FAU - Kohara, Kenji
AU  - Kohara K
AD  - Department of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, 
      Kurashiki, Japan.
FAU - Tatsumi, Fuminori
AU  - Tatsumi F
AD  - Department of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, 
      Kurashiki, Japan.
FAU - Nakanishi, Shuhei
AU  - Nakanishi S
AD  - Department of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, 
      Kurashiki, Japan.
FAU - Mune, Tomoatsu
AU  - Mune T
AD  - Department of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, 
      Kurashiki, Japan.
FAU - Kaku, Kohei
AU  - Kaku K
AD  - Department of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, 
      Kurashiki, Japan.
FAU - Kaneto, Hideaki
AU  - Kaneto H
AD  - Department of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, 
      Kurashiki, Japan.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20210806
PL  - Switzerland
TA  - Front Endocrinol (Lausanne)
JT  - Frontiers in endocrinology
JID - 101555782
RN  - 0 (Biomarkers)
RN  - 0 (Blood Glucose)
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Immunoglobulin Fc Fragments)
RN  - 0 (Recombinant Fusion Proteins)
RN  - 0 (hemoglobin A1c protein, human)
RN  - 62340-29-8 (Glucagon-Like Peptides)
RN  - WTT295HSY5 (dulaglutide)
SB  - IM
MH  - Biomarkers/*blood
MH  - Blood Glucose/analysis
MH  - Case-Control Studies
MH  - Diabetes Mellitus, Type 2/blood/*drug therapy/pathology
MH  - Dipeptidyl-Peptidase IV Inhibitors/*therapeutic use
MH  - Drug Substitution/*statistics & numerical data
MH  - Female
MH  - Follow-Up Studies
MH  - Glucagon-Like Peptides/*analogs & derivatives/therapeutic use
MH  - Glycated Hemoglobin/analysis
MH  - Glycemic Control/*methods
MH  - Humans
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Immunoglobulin Fc Fragments/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Recombinant Fusion Proteins/*therapeutic use
MH  - Retrospective Studies
PMC - PMC8415741
OTO - NOTNLM
OT  - DPP-4 inhibitor
OT  - Hba1c
OT  - dulaglutide
OT  - glycemic control
OT  - propensity score matching
OT  - weekly GLP-1 receptor activator
COIS- KKa has been an advisor to, received honoraria for lectures from, and received 
      scholarship grants from Novo Nordisk Pharma, Sanwa Kagaku Kenkyusho, Takeda, 
      Taisho Pharma, MSD, Kowa, Sumitomo Dainippon Pharma, Novartis, Mitsubishi Tanabe 
      Pharma, AstraZeneca, Boehringer Ingelheim, Chugai, Daiichi Sankyo, and Sanofi. HK 
      has received honoraria for lectures, received scholarship grants, and received 
      research grant from Novo Nordisk Pharma, Sanofi, Eli Lilly, Boehringer Ingelheim, 
      Taisho Pharma, Sumitomo Dainippon Pharma, Takeda Pharma, Ono Pharma, Daiichi 
      Sankyo, Mitsubishi Tanabe Pharma, Kissei Pharma, MSD, AstraZeneca, Astellas, 
      Novartis, and Kowa. However, this study was not funded by the above funders. The 
      remaining authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2021/09/07 06:00
MHDA- 2022/02/12 06:00
PMCR- 2021/01/01
CRDT- 2021/09/06 05:55
PHST- 2021/05/25 00:00 [received]
PHST- 2021/07/15 00:00 [accepted]
PHST- 2021/09/06 05:55 [entrez]
PHST- 2021/09/07 06:00 [pubmed]
PHST- 2022/02/12 06:00 [medline]
PHST- 2021/01/01 00:00 [pmc-release]
AID - 10.3389/fendo.2021.714447 [doi]
PST - epublish
SO  - Front Endocrinol (Lausanne). 2021 Aug 6;12:714447. doi: 
      10.3389/fendo.2021.714447. eCollection 2021.